Vanguard Information Technology ETF (VGT)
| Assets | $133.27B |
| Expense Ratio | 0.09% |
| PE Ratio | 26.66 |
| Forward PE | 17.05 |
| Shares Out | 1.24B |
| Dividend | $0.47 (0.43%) |
| Ex-Dividend Date | Sep 23, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 11.43% |
| Volume | 6,851,202 |
| Open | 110.70 |
| Previous Close | 111.98 |
| Day's Range | 108.94 - 112.08 |
| 52-Week Low | 83.09 |
| 52-Week High | 130.66 |
| Beta | 1.37 |
| Holdings | 323 |
| Inception Date | Jan 26, 2004 |
About VGT
Fund Home PageThe Vanguard Information Technology ETF (VGT) is an exchange-traded fund that mostly invests in technology stocks. The fund tracks a market cap-weighted index of companies in the US information technology sector. VGT was launched on Jan 26, 2004 and is issued by Vanguard.
Top 10 Holdings
63.59% of assets| Name | Symbol | Weight |
|---|---|---|
| NVIDIA Corporation | NVDA | 17.59% |
| Apple Inc. | AAPL | 15.91% |
| Microsoft Corporation | MSFT | 11.16% |
| Micron Technology, Inc. | MU | 4.45% |
| Broadcom Inc. | AVGO | 4.11% |
| Advanced Micro Devices, Inc. | AMD | 3.68% |
| Intel Corporation | INTC | 1.99% |
| Cisco Systems, Inc. | CSCO | 1.60% |
| Lam Research Corporation | LRCX | 1.56% |
| Palantir Technologies Inc. | PLTR | 1.55% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 23, 2026 | $0.1465 | Sep 25, 2026 |
| Jun 24, 2026 | $0.1384 | Jun 26, 2026 |
| Mar 24, 2026 | $0.09298 | Mar 26, 2026 |
| Dec 17, 2025 | $0.09463 | Dec 19, 2025 |
| Sep 24, 2025 | $0.10733 | Sep 26, 2025 |
| Jun 26, 2025 | $0.08785 | Jun 30, 2025 |
Performance
VGT had a total return of 16.66% in the past year, including dividends. Since the fund's inception, the average annual return has been 14.53%.
News
ETF Edge on how the Nvidia turmoil could impact the AI trade
While the controversy around Nvidia CEO Jensen Huang continues to unfold, many investors are wondering about the potential ripple effects around the larger AI economy and the tech trade. Yorkville Ive...
3 ETFs That Could Deliver 20%+ Upside, According to the AI Analyst
TipRanks’ ETF AI Analyst sees more than 20% upside potential in the Vanguard Information Technology ETF ($VGT), Energy Select Sector SPDR Fund ($XLE), and Nuveen ESG Large-Cap Growth ETF ($NULG). The ...
3 ‘Strong Buy’ Technology ETFs with More Than 30% Upside
The Technology Select Sector SPDR Fund (XLK), iShares U.S. Technology ETF (IYW), and Vanguard Information Technology ETF (VGT) are three technology exchange-traded funds (ETFs) rated “Strong Buy,” wit...
Vanguard’s VGT or BlackRock’s ARTY: Which Tech ETF Offers Better AI Exposure in 2026?
Investors seeking tech and AI exposure can choose between broad tech funds and more focused AI funds. The Vanguard Information Technology ETF ($VGT) offers broad exposure to U.S. tech stocks…
These 3 ETFs Could Generate More Than 12% Returns, Says the AI Analyst
TipRanks’ ETF AI Analyst expects iShares Core S&P 500 ETF ($IVV), Vanguard Information Technology ETF ($VGT), and Alerian MLP ETF ($AMLP) to deliver more than 12% returns. The AI Analyst’s bullish sta...
Missed this Vanguard ETF's 37% rally? Here's what $10,000 could do next
A $10,000 investment in Vanguard's Information Technology ETF at the start of 2026 would be worth $13,700 before distributions and trading costs, after VGT climbed 37% this year. That makes the fund e...
Yields & Global Value: Inside Vanguard's Top 8 ETFs for September
In September, Vanguard ETFs overall recorded a mix of steady market performance, some volatility, and significant dividend distributions, with investors pouring substantial capital into its funds. Sta...
3 ‘Strong Buy’ Technology ETFs That Could Rally More Than 25%
Vanguard Information Technology ETF ($VGT), Technology Select Sector SPDR Fund ($XLK), and iShares Semiconductor ETF ($SOXX) are three technology exchange-traded funds (ETFs) that are rated Strong Buy...
This 24% Dividend Gets Riskier As The Market Surges
The stunning thing about this year's stock-market rally is that much of it has come in just the last couple of months.
We have had an ‘overweight waiting' on the IT sector since 2022: CFRA Research senior VP
CFRA Research senior vice president and head of technology Angelo Zino explains why Nvidia, AMD, Microsoft and Meta remain top ‘strong buy' picks amid the ongoing AI-driven tech rally on ‘Making Money...
SaaS-pocalypse Reversal? AI Memory Chips Slide, Software Finds Strength
In a reversal from the SaaS-pocalypse, software is finding strength while AI memory names like Micron (MU) and SanDisk (SNDK) are selling off. Kevin Hincks explains how this all plays into the big pic...
Vanguard Announces Share Splits for Five Equity Index ETFs
VALLEY FORGE, Pa., March 24, 2026 /PRNewswire/ -- Vanguard today announced plans to execute forward share splits for five equity index ETFs.
What next for the Nasdaq 100 Index and QQQ, VGT, and VGT ETFs?
The Nasdaq 100 Index has slumped in the past few weeks, erasing some of the gains made earlier this year when it jumped to a record high of $26,156. It dropped to $23,765, its lowest level since Septe...
Vergent Bioscience Initiates Phase 3 VISUALIZE 2 Pivotal Study of Abenacianine (VGT-309) for Tumor Visualization During Lung Cancer Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company advancing molecularly targeted intraoperative imaging, today announced the initiation of VISUALIZE 2, a Phase 3...
Worldwide Exchange: ETF Flows Week of September 29
CNBC's Frank Holland speaks with Robert Doll, CEO & CIO at Crossmark Global Investments, about the action in ETFs this week.
The Best Tech ETFs to Buy
Tech ETFs can deliver superb tax efficiency and growth potential, but investors must be aware of high volatility, concentration risk and stretched valuations.
Vergent Bioscience Presents Phase 2B VISUALIZE Results Demonstrating Abenacianine for Injection (VGT-309) with Intraoperative Molecular Imaging Improved Tumor Visualization During Lung Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor targeted imaging agents, announced new data being presented at the 2025 American Society of Cl...
Vergent Bioscience to Present Data on Abenacianine for Injection (VGT-309) at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that an abstract on abenacianine for injection (VGT-309) wi...
Tips for investing in tech now
Big tech has dominated the markets, but with tariffs and market uncertainty, what should investors do with the sector now? Ivana Delevska, Spear Invest Founder and CIO, joins Wealth to give some tips ...
Avoid the QQQ ETF, buy this Nasdaq 100 ETF alternative instead
The Invesco QQQ ETF has become one of the best-performing funds in the United States in the past few decades by tracking the Nasdaq 100 index. It has soared from about $40 during its inception and mov...
AI-themed ETFs plunge in wake of DeepSeek news
Prices of exchange-traded funds with outsize exposure to Nvidia plunged in the initial hours of trading on Monday in reaction to news that a Chinese startup has launched a powerful new artificial inte...
Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the U.S. Food & Drug Administration (FDA) has granted ...
Vergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial Evaluating Potential of Abenacianine for Injection (VGT-309) to Improve Tumor Visualization During Cancer Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced completion of patient enrollment in the company's Phase 2, ...